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ABSTRACT
Objectives Knowledge about time trends of cancer 
incidence and cancer survival in a defined region is 
an essential prerequisite for the planning of regional 
healthcare infrastructure. The aim of the study was to 
provide population- based analyses of all common tumour 
sites to assess the cancer burden in the Augsburg study 
region.
Setting Total population of the study region of Augsburg 
(668 522 residents), Southern Germany.
Participants The data obtained from the Cancer Registry 
Augsburg comprised 37 487 incident cases of malignant 
tumours (19 313 men and 18 174 women) diagnosed 
between 2005 and 2016 in the Augsburg region’s resident 
population.
Primary and secondary outcome measures We 
calculated sex- specific, age- standardised incidence rates 
and annual percent change to assess time trends. In men 
and in women, 3- year and 5- year relative survival was 
calculated and results were compared with the latest 
German estimates. Survival trends were presented for the 
most common cancers only.
Results Decreasing age- standardised incidence rates 
were observed for prostate cancer and for colorectal 
cancer in men. For oropharyngeal cancer, rates declined 
in men, but significantly increased in women. Incidence 
for female breast cancer remained stable. Five- year 
relative survival ranged between 6.4% (95% CI: 4.1% to 
10.1%) for pancreatic cancer and 97.7% (95% CI: 96.0% 
to 99.4%) for prostate cancer in men and between 10.2% 
(95% CI: 7.1% to 14.6%) for pancreatic cancer and 96.6% 
(95% CI: 93.6% to 99.6%) for malignant melanoma in 
women. Trends in 3- year survival of the five most common 
tumour sites in men showed a significant increase for lung 
and oropharyngeal cancer. In women, continuously rising 
survival trends were observed for breast cancer.
Conclusions Survival of cancer patients in the Augsburg 
study region was largely concordant with the situation 
in Germany as a whole, while incidence showed slight 
deviations in some cancer sites. Regional evaluations on 
cancer survival are a valuable instrument for identifying 
deficits and determining advances in oncological health 
management.
BACKGROUND
In Germany, approximately 600 000 people 
were diagnosed with cancer in 2018, and 
for almost 250 000 cancer patients, the 
disease was fatal.1 Increasing age is associ-
ated with a higher risk of developing cancer.2 
Due to Germany’s ageing population, a 
distinct increase in cancer prevalence is to 
be expected, along with a growing need for 
healthcare resources. To face this challenge, 
the National Cancer Plan was initiated in 
Germany in 2008 and implemented in 2011. 
The plan aimed to improve cancer screening 
and establish a comprehensive clinical cancer 
registration process. Regional evaluations on 
cancer incidence and survival are a valuable 
instrument for identifying deficits and deter-
mining advances in oncological healthcare.
For a long time, German estimations of 
cancer survival were based predominantly 
on data of the Cancer Registry Saarland.3 
The most recent studies on cancer survival 
in Germany analysed data of different cancer 
registries, but the survival data of Bavaria 
have not been included in comparative 
regional investigations so far.4–9 Regional 
differences between the federal states were 
found for incidence and mortality, varying 
by sex and primary cancer site.4 However, 
Strengths and limitations of this study
 ► Cancer registry data can serve as an instrument for 
the evaluation of oncological healthcare. Analyses of 
regional data can help to identify areas and targets 
of priority assessing directly the needs of the resi-
dent population.
 ► This study presents population- based data on rela-
tive survival and trends in incidence of all common 
tumour sites for the Augsburg study region, a geo-
graphically defined area in which large epidemiolog-
ical long- term cohorts are ongoing.
 ► The epidemiological Cancer Registry Augsburg 
provided data of all confirmed cancer cases of the 
catchment area of Augsburg and thus ensures high 
data quality.
 ► For some more rare entities, regional evaluations on 
cancer survival are facing low case numbers.
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there is a lack of region- specific investigations dealing 
with population- based cancer registry data. Focusing on 
the needs of all oncology patients, survival analysis in a 
geographically defined region can serve as an indicator 
for the effectiveness of oncological healthcare in the resi-
dent population.3 The region of Augsburg, covering the 
city of Augsburg and the surrounding counties Augsburg 
and Aichach- Friedberg, comprises about 668 522 (2016) 
residents.10 The Augsburg region is of special importance 
because its population is used in the recruitment of the 
large, epidemiological cohorts of the KORA and NAKO 
studies.11
In Bavaria, comprehensive coverage in the registry 
of cancer data has been carried out since 2002.12 The 
Cancer Registry Augsburg records all kinds of incident 
malignant neoplasms and thus provides population- based 
data for the Augsburg region. To our knowledge, this is 
the first study concentrating on cancer registry data in 
the region of Augsburg. The aim of this study is to assess 
cancer burden in the Augsburg study region, providing 
population- based estimates of relative survival and trends 
in incidence of all common tumour sites to contribute to 
the planning of regional healthcare infrastructure.
METHODS
Cancer registry data
The Cancer Registry Augsburg is the official cancer 
registry of Swabia, recording population- based epide-
miological data on a legal basis. As all practitioners and 
medical facilities report their cases to the Cancer Registry 
Augsburg, it provides the total number of incident 
neoplasms of the Augsburg region. Quality indicators for 
the most common cancer sites are listed in the online 
supplementary table 1. Registration exists for all kinds of 
malignant neoplasms as well as their non- invasive stages. 
The recorded data comprise information about personal 
and epidemiological features of the patient, that is, date 
of birth, sex, date of first diagnosis, the cancer diagnosis 
according to ICD-10 classification and potentially the date 
of death. The vital status of the patients recorded with a 
cancer diagnoses was updated regularly by means of death 
certificates. For the entire study period, death certificates 
were provided for all of Swabia from the local health 
authorities of the region. Linkage of data is performed 
by demographic data. In case of death, this information 
is registered with the local authority of the person’s place 
of residence. The information on data of cancer patients 
treated in other regions are passed to the responsible 
regional cancer registry via the Confidentiality Office 
of the Bavarian Cancer Registry. For the present study, 
the original data set comprised 37 487 incident cases of 
malignant neoplasms, with exception of non- melanoma 
skin cancer, diagnosed between 2005 and 2016 in patients 
residing in the region of Augsburg.
Statistical analyses
The study aimed to analyse the occurrence and distri-
bution of cancer diseases in the Augsburg region. Data 
were given separately for the city of Augsburg and both 
counties and were stratified according to sex and age 
groups (<15, 15–34, 35–44, 45–54, 55–64, 65–74, 75+). 
Ten- year intervals were used from the age of 35 years 
onwards considering that cancer risk increases with age. 
Sex- specific absolute and relative frequencies of the most 
common cancer localisations were calculated, including 
the entire study period to achieve more stable results. 
Age- standardised incidence rates were presented for the 
Table 1 Malignant tumours in the resident population of the Augsburg study region (City of Augsburg, County of Augsburg 








County of Aichach- Friedberg,
n=6061
n % n % n % n %
Sex
  Male 19 313 51.5 8661 50.8 7527 52.3 3125 51.6
  Female 18 174 48.5 8383 49.2 6855 47.7 2936 48.4
Age at first diagnosis
  <15 190 0.5 75 0.4 74 0.5 41 0.7
  15–34 864   2.3 390 2.3 331 2.3 143 2.4
  35–44 1671   4.5 709 4.2 646 4.5 316 5.2
  45–54 4396   11.7 1798 10.6 1789 12.4 809 13.4
  55–64 7717   20.6 3389 19.9 2999 20.9 1329 21.9
  65–74 11 501 30.7 5227 30.7 4462 31.0 1812 29.9
  75+ 11 148 29.7 5456 32.0 4081 28.4 1611 26.6
DCO cases 527 1.4 146 1.0 171 1.2 192 3.2
Cases detected 
at autopsy
23 0.1 16 0.9 7 0.1 – –
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years 2005 to 2016 for men and for women, using 5- year 
age groups. The analysis was performed using the mean 
population per calendar year (calculated for each year by 
taking the average of the population on 31 December in 
the current and preceding year, as listed in the population 
tables of the city of Augsburg, the county of Augsburg and 
the county of Aichach- Friedberg) and rates were tabu-
lated per 100 000 men and women per year.13 The popu-
lation tables were obtained from the Federal Statistical 
Office of Bavaria.14 The old European standard popu-
lation was used for direct standardisation of incidence 
rates.15 Annual percent change (APC) was computed by 
linear regression of logarithmised incidence rates using 
the year of diagnosis as the independent variable (Join-
point Regression Program, V.4.7.0.0, National Cancer 
Institute).16 To describe the trend of incidence rates for 
the study period joinpoints were identified. APC and its 
CIs were determined for the interval between the defined 
trend- change points.
For the total study period, estimates of relative three3- 
year and 5- year survival were presented. Trend analysis of 
sex- specific, 3- year relative survival of the most common 
cancers was performed, summarising the year of first diag-
nosis into three time periods (2005/2007, 2008/2010 and 
2011/2013). Cases detected by autopsy or death certifi-
cate only (DCO)were excluded from survival analysis.17 
We excluded patients aged under 15 years at first diagnosis 
as well due to considerable differing prognosis of chil-
dren and adults.17 Patients with multiple primary cancers, 
localised in different sites, were kept in the study.18 Rela-
tive survival can be considered as the survival from cancer 
after adjusting for other causes of death and is defined as 
the ratio of the observed survival to the expected survival 
during a specified interval.19 The expected survival time 
of age- matched and sex- matched individuals was calcu-
lated using life tables for the general German population 
applying the Ederer II method.20 The Federal Office of 
Statistics (‘Statistisches Bundesamt’) provided popula-
tion data corresponding to the study period.21 All anal-
yses were performed in SAS, V.9.4 and R, V.3.5.1.
Patient and public involvement
This research was done without direct patient or public 
involvement.
RESULTS
Most common cancer entities in the Augsburg region
Overall, malignancies were almost equally frequent in 
both sexes with a slight excess in men, and results were 
comparable for the city and both counties (table 1). 
Breast cancer was the most common malignant disease in 
women (32.3%) and the prostate was the leading cancer 
site (23.2%) in men (table 2). Colorectal cancer (CRC) 
was the second most common cancer in men (14.8%) as 
well as in women (12.5%), followed by malignancies of 
the lung in both sexes (males: 12.1%, females: 6.2%).
Sex-specific trends in incidence rates
During the study- period, age- standardised incidence rates 
(figure 1) in both sexes revealed a decline in CRC, which 
was more pronounced in men (APC=−3.7%) than in 
women (APC=−1.2%) (table 3). For carcinoma of the oral 
Table 2 Absolute and relative frequencies: incident 
malignant tumours of the years 2005–2016 in the Augsburg 
study region by sex and site (n=37 487)
Site
ICD-10 Men Women
n % n %
Lip/oral cavity/
pharynx
C00–C14 761 3.94 273 1.50
Oesophagus C15   403 2.09 108 0.59
Stomach C16 724 3.75   517 2.84
Colorectum C18–C21 2862 14.82 2264 12.46
Liver C22 539 2.79 160 0.88
Gallbladder/biliary 
tract
C23–C24 180 0.93 201 1.11
Pancreas C25 627 3.25 619 3.41
Larynx C32 247 1.28   32 0.18
Lung C33–C34 2331 12.07 1128 6.21
Malignant 
melanoma of the 
skin
C43 984 5.10 878 4.83




C46–C49 178 0.92 155 0.85
Breast C50 38 0.20 5876   32.33
Vulva C51 195 1.07
Cervix uteri C53 373 2.05
Corpus uteri C54–C55 1022   5.62
Ovary C56 703   3.87
Prostate C61 4475 23.17
Testis C62 334 1.73
Kidney C64 709 3.67 396 2.18
Urinary bladder C67 657 3.40 244 1.34
Central nervous 
system
C70–C72 315 1.63 254 1.40
Thyroid C73 224 1.16   547 3.01
CUP C80 360 1.86 369 2.03
Hodgkin’s 
lymphoma
C81 140 0.72   83   0.46
Non- Hodgkin’s 
lymphoma
C82–C88   730 3.78 631 3.47
Multiple myeloma C90 253 1.31 229 1.26
Leukaemia C91–C95 628 3.25 455   2.50
Other 
localisations
503 2.60 448   2.46
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cavity and the pharynx, the age- standardised incidence 
rates indicated a decline in men, but a clear increase 
in women (APC=4.5%). For lung cancer, rather stable 
age- standardised incidence rates were observed in men 
and women. Trend changing points were identified for 
malignant melanoma of the skin (online supplementary 
table 2). In both sexes, age- standardised incidence rates 
peaked in 2009 (men)/2010 (women), decreasing after-
wards to less than the initial rate of the year 2005 (APC 
men= −5.5%; APC women= −11.3%). In women, rather 
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Table 3 Age- standardised incidence of malignant tumours in the Augsburg study region by sex and site—incident cases of 
the years 2005–2016
Site 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 APC (95% CI)
Men (n=19 313)
  Lip/oral cavity/
pharynx
24.3 17.6 15.4 16.5 16.1 14.4 13.0 15.9 18.4 16.9 15.4 15.7 −2.0 (−4.6 to 0.7)
  Oesophagus 9.4 7.0 8.7 7.1 7.0 9.3 11.1 6.7 7.2 8.3 10.6 6.8 0.2 (−3.3 to 3.9)
  Stomach 15.5 13.7 19.2 14.0 16.0 12.4 12.7 15.5 13.0 14.9 12.9 11.2 −2.3 (−4.6 to 0.1)
  Colorectum 72.2 60.0 62.3 61.8 60.1 55.5 56.3 52.0 54.1 54.5 44.8 40.8 −3.7 (−4.8 to −2.5)
  Liver 8.6 10.6 11.0 10.8 8.0 7.8 9.3 11.0 12.2 9.7 12.4 11.4 1.9 (−0.7 to 4.6)
  Gallbladder/
biliary tract
2.9 3.6 2.8 2.2 2.7 2.5 2.8 4.3 4.4 2.7 5.5 3.5 4.8 (−0.1 to 9.8)
  Pancreas 12.6 11.7 12.9 12.5 10.4 9.8 11.8 11.8 12.0 13.7 11.4 14.0 0.7 (−1.2 to 2.6)
  Larynx 7.2 5.0 3.3 5.1 5.1 6.5 3.4 6.2 5.3 3.8 3.8 5.8 −1.7 (−6.1 to 2.8)
  Lung 42.9 47.0 42.7 47.6 50.7 45.8 43.2 44.4 51.1 42.7 44.9 36.9 −0.7 (−2.4 to 0.9)
  Malignant 
melanoma of 
the skin
16.8 16.5 20.2 21.2 26.9 23.4 23.0 23.2 16.4 17.3 21.2 16.3 −0.6 (−4.0 to 3.0)
  Mesothelioma 1.0 3.1 2.4 0.8 2.3 1.6 1.7 2.3 2.8 1.7 1.5 2.1 −0.8 (−7.4 to 6.1)
  Soft tissue 4.1 4.3 5.8 2.5 8.0 4.1 5.6 2.4 2.9 2.7 3.1 3.2 −4.6 (−12.1 to 3.4)
  Breast 0.6 1.1 0.2 0.5 1.4 0.6 0.4 0.0 0.2 0.9 1.9 1.0 –
  Prostate 110.7 107.4 117.3 92.1 92.9 100.3 105.9 85.7 83.7 58.4 47.8 45.1 −6.7 (−9.7 to −3.7)
  Testis 6.1 7.0 9.1 9.5 11.4 9.8 10.2 7.8 9.3 9.2 7.8 7.3 0.1 (−3.4 to 3.8)
  Kidney 13.5 13.0 13.8 13.6 16.7 13.2 13.9 15.7 18.7 15.8 11.7 13.2 0.6 (−2.0 to 3.4)
  Urinary bladder 13.4 10.1 10.0 9.8 12.9 15.8 14.9 12.3 13.1 13.8 10.2 11.0 0.3 (−3 to 3.7)
  Central nervous 
system
6.3 8.1 5.8 7.9 8.6 8.7 5.90 6.8 6.8 5.8 6.5 6.6 −1.2 (−4.1 to 1.7)
  Thyroid 3.3 5.3 7.5 5.9 5.3 5.4 4.3 5.6 5.8 2.3 5.4 4.7 −1 .5 (−6.4 to 3.6)
  CUP 7.7 8.8 7.8 5.9 7.8 7.1 8.0 7.1 5.6 4.7 5.4 7.7 −2.5 (−5.4 to 0.5)
  Hodgkin's 
lymphoma
3.7 1.7 3.0 3.7 3.5 3.3 4.7 5.1 4.6 2.5 2.6 3.3 1.3 (−4.8 to 7.7)
  Non- Hodgkins 
lymphoma
13.5 14.8 15.9 15.8 15.9 17.7 15.7 13.2 13.3 17.4 12.2 12.4 −1.0 (−3.4 to 1.4)
  Multiple 
myeloma
3.5 7.1 3.9 3.5 7.1 6.8 5.5 6.0 3.6 4.3 3.8 4.0 1.9 (−8.1 to 13.0)
  Leukaemia 10.8 13.3 17.3 11.7 18.6 12.5 12.8 11.4 16.0 12.4 11.6 8.5 −1.9 (−5.9 to 2.2)
Women (n=18 174)
  Lip/oral cavity/
pharynx
3.4 3.9 5.0 3.1 4.4 5.3 5.7 5.8 7.3 6.8 4.3 3.4 4.5 (0.3 to 8.9)
  Oesophagus 1.4 1.3 1.3 2.5 1.2 1.2 1.5 2.1 2.6 2.5 1.6 1.4 3.6 (−2.2 to 9.7)
  Stomach 8.5 9.1 8.9 6.1 9.6 8.0 4.5 6.3 7.6 8.1 7.3 8.5 −2.5 (−6.1 to 1.3)
  Colorectum 37.4 35.9 38.5 33.7 33.7 33.6 33.4 35.6 32.8 39.4 35.3 37.4 −1.2 (−3.0 to 0.7)
  Liver 2.1 1.3 1.9 2.1 2.8 2.6 3.4 3.0 1.7 2.8 2.0 2.1 3.0 (−1.8 to 8.1)
  Gallbladder/
biliary tract
2.5 2.3 3.5 3.0 3.1 3.0 3.2 2.3 3.5 2.5 2.8 2.5 −0.4 (−3.4 to 2.6)
  Pancreas 7.6 6.8 6.4 10.6 9.7 10.0 9.2 12.0 8.6 8.2 9.8 7.6 1.7 (−1.7 to 5.3)
  Larynx 0.6 0.8 0.2 0.3 0.3 0.2 1.1 0.6 1.2 0.3 0.8 0.6 4.8 (−8.1 to 19.6)
  Lung 19.3 14.7 20.0 23.7 18.2 20.5 17.5 19.6 21.4 23.9 18.5 19.3 1.0 (−1.4 to 3.5)
  Malignant 
melanoma of 
the skin
17.4 13.7 19.2 19.9 23.2 23.6 21.3 18.7 18.1 12.2 10.3 14.2 −2.9 (−7.4 to 1.7)
  Mesothelioma 0.4 0.0 0.3 0.3 0.2 0.0 0.3 0.0 0.4 0.3 0.0 0.6 –
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stable age- standardised incidence rates could be observed 
for breast cancer (APC=0.1%). The data revealed a distinct 
decline in prostate cancer since 2012 regarding the crude 
(online supplementary table 3) and age- standardised 
incidence rates (2012–2016: APC=−18.0%). Sex- specific 
crude mortality rates corresponding to the study period 
were presented in online supplementary table 4.
Sex-specific relative cancer survival
The 5- year relative survival turned out to be highest for 
prostate cancer (97.7%) and for testicular cancer (97.2%) 
(table 4). A favourable prognosis was observed for mela-
noma of the skin with a 5- year relative survival of 95.3% in 
men and 96.6% in women. For carcinoma of the breast, 
survival estimates in women reached 88.6% (figure 2). 
With 5- year survival rates of 18.1% in men and 20.8% in 
women, the prognosis for patients with lung cancer was 
still quite poor. Five- year survival was the worst for carci-
noma of the pancreas with rates of 6.4% in males and 
10.2% in females. Survival was almost equally as poor for 
carcinoma of the liver, with 5- year rates of 14.1% for men 
and 19.8% for women. Only slight sex differences in the 
5- year relative survival could be observed for CRC, with 
rates of 69.3% in men and 70.4% in women.
For the majority of the presented cancer sites, no signifi-
cant change was observed in the 3- year relative survival rates 
over the study period (table 5). In men, lung and oropha-
ryngeal cancer showed an increase in 3- year relative survival 
rates between 2005/2007 and 2011/2013 (figure 3). In 
women, rising 3- year relative survival rates were found for 
breast cancer and for carcinoma of the ovary.
DISCUSSION
The present study outlines trends in cancer incidence 
and survival in the population of the Augsburg region. 
Regarding the most frequent cancer entities specifically, 
in men incidence rates for CRC and prostate cancer 
decreased, while the rates for lung cancer remained rela-
tively stable during the period of 2005 to 2016. After a 
peak in 2009/2010, incidence rates for malignant mela-
noma declined in both sexes. In women, the incidence 
rates for oropharyngeal cancer increased, and the rates 
for lung and for breast cancer remained rather stable. 
Trends in 3- year survival of the most common tumour 
sites in men showed an increase in lung cancer and carci-
noma of the oral cavity and the pharynx. In women, rising 
trends in survival were observed for breast cancer and for 
ovarian cancer.
Observing three time- periods from 2005/2007 to 
2011/2013, the Augsburg data suggest an increase 
in breast cancer survival. The 5- year relative survival 
reached 88.6% in females, approximately coinciding 
with the latest average German rates (87%22). During the 
study period, age- standardised incidence rates for breast 
cancer remained rather stable. More effective treatment 
methods, and early detection of tumours,23 were the 
main reasons for the decrease of mortality regarding 
this tumour site.24 Considerably higher survival is seen in 
patients with early- stage, compared with advanced- stage 
breast cancers.23 25 To diagnose breast cancer at an early 
stage, a systematic mammography screening programme 
(MSP) has been implemented into routine medical care 
Site 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 APC (95% CI)
  Breast 105.3 111.5 101.2 112.9 111.9 118.8 116.4 108.9 113.5 119.7 108.5 99.0 0.1 (−1.1 to 1.2)
  Vulva 2.2 2.2 3.3 2.5 3.0 3.8 3.5 4.2 2.6 2.9 2.0 2.8 0.5 (−4.1 to 5.3)
  Cervix uteri 8.8 7.0 7.5 7.3 5.9 7.7 7.2 10.6 10.0 8.6 8.2 7.7 1.5 (−1.5 to 4.6)
  Corpus uteri 15.9 17.4 21.5 15.6 20.1 16.2 15.8 18.3 17.7 17.7 19.9 17.9 0.4 (−1.6 to 2.4)
  Ovary 10.3 15.1 14.3 12.6 13.7 15.1 10.2 9.1 12.6 13.4 11.7 9.0 −2.1 (−5.2 to 1.1)
  Kidney 7.6 7.7 6.8 6.3 9.5 7.6 5.5 6.6 8.5 4.8 4.50 3.3 −4.7 (−8.9 to −0.2)
  Urinary bladder 2.9 3.5 4.1 4.6 2.8 3.7 3.6 2.9 4.9 3.1 2.7 2.7 −1.4 (−5.4 to 2.8)
  Central nervous 
system
5.4 3.3 5.9 4.3 4.2 6.7 7.6 3.4 6.4 4.6 3.7 5.5 0.2 (−5.1 to 5.8)
  Thyroid 12.2 12.6 15.5 12.8 12.2 12.3 11.4 14.9 9.1 13.1 10.9 11.2 −1.5 (−3.9 to 1.0)
  CUP 5.6 6.6 6.7 6.8 4.8 3.1 6.7 3.5 6.2 3.1 5.5 4.4 −3.2 (−7.8 to 1.5)
  Hodgkin’s 
lymphoma
1.5 2.0 1.5 4.0 1.5 1.2 1.1 1.2 0.7 3.2 3.1 2.8 2.9 (−6.2 to 13.0)
  Non- Hodgkin’s 
lymphoma
13.7 11.3 10.0 15.1 9.9 12.0 11.5 11.2 9.1 10.7 7.1 7.7 −4.0 (−6.9 to −1.0)
  Multiple 
myeloma
3.7 4.7 3.7 5.2 3.6 4.6 2.4 3.2 3.1 3.7 2.1 2.5 −4.8 (−8.5 to −0.9)
  Leukaemia 8.1 8.4 9.4 8.3 11.4 9.3 7.6 7.0 9.0 8.4 5.1 6.1 −3.1 (−6.4 to 0.3)
Incidence rate per 100 000 men and women; age- standardisation by the use of ‘old European standard population’.
All significant results are given in bold format.
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in Germany in 2005.25 The programme targets all women 
aged between 50 and 69 years and biannually invites 
them to mammography screening.25 In 2009, compre-
hensive coverage of the MSP was achieved in the Augs-
burg region, but incidence rates have not reflected the 
effects of the MSP observed in Germany as a whole so 
far. However, a detailed investigation of incidence rates 
of UICC (Union Internationale Contre le Cancer) stages 
might give further insights regarding the impact of the 
MSP on the disease course of breast cancer. Incidence 
rates of breast cancer showed a slightly decreasing trend 
in women aged 50–69, mainly caused by the decline in 
rates of regional cancers (figure 4). However, localised 
cancers did not clearly increase with introduction of the 
MSP in the target group. Enhanced by increasing the use 
of imaging techniques during the past decade, opportu-
nistic screening might have had an impact on these find-
ings as well.
Major risk factors for breast cancer relate to fertility 
and childbearing, for example, parity and breastfeeding 
Table 4 Malignant tumour 3- year and 5- year relative survival and its 95% CI in the Augsburg study region by sex and site— 













49.6 (44.8 to 54.9) 43.2 (38.4 to 48.7) 66.5 (58.4 to 75.8) 61.0 (52.3 to 71.2)
Oesophagus (C15) 30.3 (24.7 to 37.3) 25.7 (20.2 to 32.7) 37.6 (25.8 to 54.8) 23.9 (14.0 to 40.8)
Stomach (C16) 44.3 (39.2 to 50.0) 41.4 (36.0 to 47.5) 47.1 (41.1 to 54.0) 43.4 (37.0 to 50.8)
Colorectum (C18–C21) 74.6 (72.2 to 77.2) 69.3 (66.5 to 72.3) 73.4 (70.6 to 76.4) 70.4 (67.2 to 73.7)
Liver (C22) 18.9 (14.4 to 24.8) 14.1 (10.0 to 19.7) 28.5 (19.7 to 41.3) 19.8 (12.2 to 32.1)
Gallbladder/biliary tract (C23–
C24)
33.8 (24.3 to 47.2) 24.5 (15.7 to 38.4) 20.5 (14.0 to 30.0) 16.4 (10.5 to 25.7)
Pancreas (C25) 9.8 (6.9 to 13.8) 6.4 (4.1 to 10.1) 11.9 (8.6 to 16.4) 10.2 (7.1 to 14.6)
Larynx (C32) 72.2 (64.3 to 81.1) 65.0 (56.3 to 75.1) 47.6 (28.1 to 80.7) 49.0 (28.9 to 83.0)
Lung (C33–C34) 21.0 (18.7 to 23.5) 18.1 (15.9 to 20.6) 27.1 (23.6 to 31.0) 20.8 (17.6 to 24.5)
Malignant melanoma of the 
skin (C43)
95.6 (92.8 to 98.5) 95.3 (91.8 to 99.0) 98.1 (95.9 to 100.4) 96.6 (93.6 to 99.6)
Mesothelioma (C45) 24.3 (15.0 to 39.3) 18.0 (9.7 to 33.3) 30.2 (11.1 to 82.3) 32.4 (11.9 to 88.3)
Soft tissue without 
mesothelioma (C46–C49)
67.6 (58.4 to 78.2) 69.8 (60.0 to 81.3) 69.5 (60.2 to 80.2) 63.0 (53.1 to 74.8)
Breast (C50) 69.0 (49.6 to 95.8) 61.0 (40.6 to 91.8) 91.7 (90.4 to 92.9) 88.6 (87.1 to 90.1)
Vulva (C51)     67.8 (58.3 to 78.8) 62.6 (52.3 to 74.8)
Cervix uteri (C53)     71.4 (65.0 to 78.3) 67.2 (60.5 to 74.7)
Corpus uteri (C54–C55)     85.4 (81.9 to 89.1) 82.5 (78.4 to 86.8)
Ovary (C56)     48.0 (43.2 to 53.3) 40.2 (35.5 to 45.6)
Prostate (C61) 96.5 (95.1 to 97.9) 97.7 (96.0 to 99.4)     
Testis (C62) 97.4 (94.8 to 100.0) 97.2 (94.5 to 100.0)     
Kidney (C64) 81.9 (77.1 to 87.0) 79.8 (74.3 to 85.7) 76.6 (70.6 to 83.1) 76.2 (69.6 to 83.4)
Urinary bladder (C67) 61.3 (55.6 to 67.5) 58.1 (51.8 to 65.1) 48.4 (40.1 to 58.4) 48.4 (39.6 to 59.3)
Central nervous system (C70–
C72)
29.2 (23.1 to 37.0) 24.2 (18.5 to 31.7) 33.3 (26.2 to 42.3) 28.1 (21.4 to 36.9)
Thyroid (C73) 96.5 (91.5 to 101.8) 95.1 (89.2 to 101.5) 95.3 (92.5 to 98.2) 95.9 (92.9 to 99.0)
CUP (C80) 18.8 (13.9 to 25.3) 16.0 (11.3 to 22.6) 17.6 (12.8 to 24.1) 15.8 (11.0 to 22.7)
Hodgkin’s lymphoma (C81) 89.2 (81.6 to 98.0) 87.6 (78.8 to 97.4) 92.3 (84.0 to 101.4) 94.2 (85.7 to 103.6)
Non- Hodgkin’s lymphoma 
(C82–C88)
75.5 (70.8 to 80.5) 73.2 (68.0 to 78.8) 75.3 (70.5 to 80.5) 74.6 (69.3 to 80.3)
Multiple myeloma (C90) 59.5 (51.4 to 68.8) 53.0 (44.5 to 63.2) 58.7 (50.6 to 68.1) 47.5 (39.2 to 57.7)
Leukaemia (C91–C95) 70.3 (64.8 to 76.3) 67.2 (61.2 to 73.9) 65.8 (59.7 to 72.6) 62.5 (55.9 to 69.7)
APC, annual percent change; RES, relative survival (%).
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duration,26 27 and the utilisation of hormone replace-
ment therapy.28 None of these factors may have changed 
distinctly during the study period. Common life- style 
factors, for example, high level of alcohol consumption, 
obesity and physical inactivity increase the risk for the 
occurrence of breast cancer as well.27 In the Augsburg 
region, between 1999 and 2001, 35.6% of the popula-
tion aged 25–74 years were found to have a high alcohol 
intake.29 Rising trends in the prevalence of obesity were 
observed between 1989 and 2001, though the prevalence 
for physical activity increased distinctly in the same time.29
For carcinoma of the cervix, no clear time trend of age- 
standardised incidence was seen in the Augsburg region, 
but rates have remained stable in Germany for the last 15 
years.22 Five- year relative survival in the Augsburg region 
(67.2%) was as high as in the whole of Germany (67%22). 
As human papilloma virus (HPV) is a main risk factor, 
early HPV vaccination is recommended by the Standing 
Committee on Vaccination (STIKO) for girls since 2007 
and for boys since 2018.30 In 2015, lowest rates in HPV 
vaccination in 17- year old girls within Germany were seen 
in Bavaria (34.2%).31 Screening for cervical cancer is 
part of the German national statutory cancer screening 
programme and is performed by Pap smear test once a 
year for women aged 20 years and above. No systematic 
screening programme was implemented in the study 
period, but started in 2020.
Lung cancer incidence was approximately twice as 
high in men compared with women, and was distinctly 
higher than the average German rates.22 Five- year rela-
tive survival reached 18.1% in men and 20.8% in women 
in the Augsburg region, which is comparable to the 
latest Germany- wide rates of 15% in men and 21% in 
women.22 Overall, flat survival trends were recorded 
worldwide for lung cancer between 1995 and 2014, but 
Germany was among the 21 countries in which survival 
increased by 5%–10%.32 In the region of Augsburg, an 
increase in 3- year relative survival between 2005/2007 
Figure 2 Malignant tumours 3- year and 5- year relative survival in the Augsburg study region for selected sites
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and 2011/2013 could be found in men, but not in 
women. The nationwide trend in age- standardised lung 
cancer incidence and mortality have shown a differen-
tial development in men and women since the 1990s, 
with continuously rising rates in females and declining 
rates in males.2 22 Tobacco smoking is the main risk factor 
for lung cancer,33 and thus, diverging time trends of 
smoking habits in both sexes are assumed to be causal for 
this development.34 Considering demographic trends, 
the rise of tobacco- associated raw mortality is likely to 
continue, and this process is estimated to persist longer 
in females than in males.35 36 In the MONICA/KORA 
Augsburg- based surveys, the age- standardised prevalence 
of smoking in the Augsburg region was found to remain 
rather stable over the study period 1989–2001, with prev-
alence reaching 26.3% for current and 31.0% for former 
smokers in the resident population between 25 and 74 
years of age.29
Table 5 Malignant tumours 3- year relative survival and its 95% CI in the Augsburg study region in three time periods 
(2005/2007, 2008/2010 and 2011/2013) by sex and site—incident cancer cases of the years 2005–2013
Site (ICD-10)
2005–2007 2008–2010 2011–2013
3- year RES (95% CI) 3- year RES (95% CI) 3- year RES (95% CI)
Men (n=14 538) n=4660 n=4890 n=4988
  Lip/oral cavity/pharynx (C00–C14) 45.9 (39.2 to 53.8) 53.5 (46.2 to 61.8) 61.6 (54.5 to 69.8)
  Oesophagus (C15) 25.2 (17.4 to 36.4) 30.9 (22.6 to 42.4) 38.0 (29.2 to 49.4)
  Stomach (C16) 48.8 (41.2 to 57.9) 36.9 (29.9 to 45.7) 44.7 (37.4 to 53.5)
  Colorectum (C18–C21) 74.7 (71.0 to 78.5) 74.5 (70.7 to 78.5) 76.6 (72.8 to 80.6)
  Liver (C22) 20.2 (13.7 to 29.8) 16.8 (10.7 to 26.1) 24.8 (18.2 to 34.0)
  Pancreas (C25) 9.0 (5.2 to 15.6) 10.0 (5.9 to 17.0) 14.9 (9.9 to 22.2)
  Lung (C33–C34) 19.4 (16.0 to 23.5) 22.8 (19.4 to 26.7) 27.1 (23.6 to 31.3)
  Malignant melanoma of the skin (C43) 94.1 (89.1 to 99.4) 96.9 (93.1 to 100.8) 99.2 (95.2 to 103.3)
  Prostate (C61) 98.1 (96.3 to 100.0) 94.2 (91.9 to 96.6) 98.0 (95.9 to 100.2)
  Testis (C62) 97.3 (93.6 to 101.2) 97.9 (94.5 to 101.5) 97.2 (93.4 to 101.2)
  Kidney (C64) 82.0 (74.8 to 90.0) 80.0 (72.8 to 88.0) 77.9 (71.2 to 85.2)
  Urinary bladder (C67) 60.0 (51.1 to 70.5) 60.1 (51.7 to 69.8) 73.9 (66.2 to 82.5)
  Central nervous system (C70–C72) 38.2 (28.1 to 52.0) 22.5 (15.0 to 33.6) 20.0 (12.6 to 31.7)
  CUP (C80) 13.3 (7.8 to 22.7) 22.0 (14.3 to 33.9) 23.4 (15.8 to 34.7)
  Non- Hodgkin’s lymphoma (C82–C88) 71.9 (64.5 to 80.2) 79.2 (72.6 to 86.3) 77.9 (70.9 to 85.7)
  Leukaemia (C91–C95) 68.5 (59.9 to 78.3) 69.9 (61.8 to 79.0) 67.0 (59.2 to 75.8)
Women (n=13 342) n=4160 n=4571 n=4611
  Lip/oral cavity/pharynx (C00–C14) 60.4 (47.7 to 76.4) 67.1 (55.0 to 81.9) 83.0 (73.5 to 93.7)
  Stomach (C16) 46.7 (38.3 to 57.1) 42.4 (34.0 to 53.0) 55.2 (45.2 to 67.3)
  Colorectum (C18–C21) 73.0 (68.8 to 77.5) 74.1 (69.8 to 78.7) 77.6 (73.4 to 82.0)
  Pancreas (C25) 10.0 (5.5 to 18.3) 12.1 (7.8 to 18.9) 11.5 (7.4 to 17.8)
  Lung (C33–C34) 26.9 (21.6 to 33.5) 29.1 (24.2 to 35.1) 25.7 (20.9 to 31.7)
  Malignant melanoma of the skin (C43) 99.5 (96.2 to 102.8) 97.4 (94.1 to 100.7) 97.1 (93.3 to 101.0)
  Breast (C50) 89.9 (87.9 to 92.0) 92.7 (91.0 to 94.6) 95.0 (93.3 to 96.7)
  Cervix uteri (C53) 72.1 (62.9 to 82.6) 72.2 (62.8 to 83.1) 77.3 (69.3 to 86.3)
  Corpus uteri (C54–C55) 82.7 (77.3 to 88.5) 87.3 (82.1 to 92.8) 88.4 (83.4 to 93.6)
  Ovary (C56) 41.7 (34.9 to 49.9) 52.4 (45.3 to 60.6) 66.3 (58.6 to 75.0)
  Kidney (C64) 82.8 (74.3 to 92.2) 73.8 (64.8 to 84.0) 75.9 (66.8 to 86.2)
  Central nervous system (C70–C72) 39.1 (27.9 to 54.8) 28.0 (18.6 to 42.1) 27.4 (18.8 to 40.1)
  Thyroid (C73) 94.5 (90.3 to 99.0) 96.4 (92.0 to 101.0) 98.6 (95.3 to 102.0)
  CUP (C80) 20.0 (13.1 to 30.6) 16.0 (9.4 to 27.3) 17.4 (10.7 to 28.4)
  Non- Hodgkin’s lymphoma (C82–C88) 74.9 (67.4 to 83.4) 76.4 (69.5 to 84.1) 75.0 (67.7 to 83.2)
  Leukaemia (C91–C95) 64.8 (55.6 to 75.5) 69.2 (60.4 to 79.3) 58.0 (48.0 to 70.0)
RES, relative survival (%)
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Oropharyngeal cancers are heterogeneous in respect 
to localisation and morphology. This is reflected in a 
differing susceptibility to risk factors. Major risk factors 
are either tobacco smoking combined with high alcohol 
intake, which together have a synergistic effect, or 
HPV infection.22 Cancer of the oral cavity, the tongue 
and the pharynx, which are particularly susceptible to 
smoking and alcohol intake, are more likely to be found 
in men.22 In contrast, women are more often affected by 
cancer of the oropharynx, which are more likely to be 
caused by HPV infection.22 Oropharyngeal cancers have 
a better prognosis as they respond well to radiotherapy 
and chemotherapy.37 Correspondingly, the 5- year rela-
tive survival of women in the Augsburg region (61.0%) 
exceeded that of men (43.2%). Survival in women was 
comparable to the latest national estimates (63%22), 
whereas rates in men ranked below the national average 
(47%22). Trends in 3- year survival between 2005/2007 
and 2011/2013 showed a significant increase in oropha-
ryngeal cancer only in males. The age- standardised 
incidence rates for oropharyngeal cancer decreased in 
men, but increased in women, which might be due to 
the change in smoking behaviour already mentioned 
above.
Figure 3 Trend in 3- year relative survival and its 95% CI (dashed lines) in the Augsburg study region for selected sites with 
significant changes over time.
Figure 4 Breast cancer incidence, total and by stage, in women aged 50–69 years in the Augsburg study region between 2005 
and 2016, age- standardised rate per 100 000 women.
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The trends of incidence, mortality and survival during 
the study period suggest a reduced burden of CRC in the 
Augsburg region. The relative survival (69.3% in men 
and to 70.4% in women) exceeded the average German 
rates (62% in men, 63% in women (without C21)22). A 
decline of age- standardised incidence rates for CRC was 
observed in both sexes during the study period, though 
more pronounced in men than women. During the same 
time- period, CRC mortality decreased markedly only in 
males, which mainly relates to decreased mortality due 
to colon cancer (online supplementary table 4A). For 
Germany, a decrease in age- standardised incidence rates 
was reported as well, starting in 2003 and becoming 
stronger in the last years, being accompanied by markedly 
falling age- standardised mortality rates in both sexes.28 
The incidence of CRC in Germany is clearly higher in 
men than in women.38 Improved survival and decreased 
mortality are mainly due to advances in treatment,38 39 
as well as earlier detection of the disease,40 which can be 
achieved by CRC screening via occult blood test in stool 
and/or colonoscopy. Falling incidence rates may relate to 
a lower prevalence of risk factors and among others are 
attributable to the decline in smoking.28 41 Screening via 
colonoscopy in particular is likely to have contributed to 
the decrease of CRC incidence as precancerous lesions 
are already removed during the intervention. This has an 
impact on both the incidence and mortality of CRC and 
in consequence plays an important role in the preven-
tion of CRC.28 CRC screening via colonoscopy became 
part of the German national statutory cancer screening 
programme in 2002 and was offered to men and women 
age 55 and above through the end of the study period. 
However, there was no national, systematic screening 
programme for CRC in Germany during this time.
Age- standardised incidence rates for prostate cancer 
have declined markedly since 2011 in the region of Augs-
burg as well as in Germany, after steadily increasing over 
a long period of time.22 The decrease of prostate- specific 
antigen- based screening is assumed to be the cause of the 
decline in prostate cancer incidence rates,42 which had in 
the past led to the detection of many latent cancers, and 
through a shift of the time point of diagnosis, to artificially 
high survival rates.43 This might be true for the Augsburg 
region as well, as 5- year relative survival has increased to 
97.7%, exceeding the latest national average for Germany 
(89%22). While the age- standardised incidence rates in 
the region of Augsburg (105.9/100 000) were still compa-
rable to the average German rates in 2011 (113.4/100 
00022), they progressively deviated afterwards, until in 
2016 a striking divergence could be observed (Germany: 
91.6/100 000;22 Augsburg: 45.1/100 000).
There are some limitations of the present study. First, 
the data do not encompass the all DCO cases. In conse-
quence, a minor deviation of incidence rates might be 
possible. However, the proportion of DCO cases from all 
incident cancer cases in the Augsburg region was less than 
10% from 2007 onwards.12 Second, until 1 April 2017, 
reporting of incident cases was not compulsory. However, 
the Cancer Registry Augsburg was already a clinical and 
epidemiological registry leading up to that time, and 
provided data on all clinically confirmed cancer cases 
in the catchment area of Augsburg. Reliability strongly 
depends on the validity of information received by death 
certificates. Incomplete mortality registration unavoidably 
leads to the overestimation of survival rates. The major 
strength of this study is that it provides population- based 
analyses focusing on a geographically defined region and 
the needs of its resident population. Survival can serve 
as an instrument to evaluate the efficiency of oncological 
healthcare in respect to the availability of preventive and 
therapeutic options.3 Cancer registries can be used as 
an evidence base for cancer control, helping to identify 
targets of priority, allocate required resources and eval-
uate the effect of the measures performed.44
CONCLUSION
In general, cancer incidence and survival in the Augs-
burg region were comparable to the national average in 
Germany. For the majority of the cancer sites included 
in this analysis, no significant change in relative survival 
was observed during the study period. Tumour stage at 
diagnosis still is the key issue to address. Efforts should 
be taken to enhance the participation in screening 
programmes in the Augsburg region. Sex differences 
seem to have diminished, for example, in lung cancer 
and carcinoma of the oral cavity and the pharynx, likely 
due to adaption of lifestyle and associated risk factors. 
This emphasises the importance of modifiable risk 
factors such as tobacco smoking and alcohol intake, and 
should be considered in the future planning of preven-
tion programmes. Additionally, adolescent girls and boys 
should be encouraged to adhere to the recommended 
HPV vaccination schedule. The leading key issues for the 
allocation of healthcare resources in the Augsburg region 
remain the most common tumour sites. Though facing 
low numbers of cases for some entities, regional analyses 
are a valuable instrument to evaluate the efficiency of 
oncological healthcare at the local level.
Acknowledgements We thank Ms Christina König (University Medical Center 
of Augsburg, Department of Cancer Data Management, Interdisciplinary Cancer 
Center, Augsburg) for her great support in data preparation.
Contributors All authors were actively involved in the planning of the study. NG, 
CM and JL contributed substantially to the conception and design of the study. GS 
and MT were in charge of the acquisition of data. NG analysed and interpreted the 
data with feedback from JL, JM- N and CM. NG drafted and revised the manuscript 
based on comments, which were provided by all authors. JL, JM- N, MT, GS and CM 
revised the article critically for important intellectual content. All authors approved 
the final version of the manuscript to be published.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in 
the design, or conduct, or reporting or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.
 on N
ovem












pen: first published as 10.1136/bm





12 Grundmann N, et al. BMJ Open 2020;10:e036176. doi:10.1136/bmjopen-2019-036176
Open access 
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Nina Grundmann http:// orcid. org/ 0000- 0002- 5715- 2406
REFERENCES
 1 International Agency for Research on Cancer. Germany, source: 
Globocan, 2018. Available: https:// gco. iarc. fr/ today/ data/ factsheets/ 
populations/ 276- germany- fact- sheets. pdf [Accessed 01 Aug 2019].
 2 Haberland J, Bertz J, Wolf U, et al. German cancer statistics 2004. 
BMC Cancer 2010;10:52.
 3 Nennecke A, Brenner H, Eberle A, et al. [Cancer survival analysis in 
Germany--heading towards representative and comparable findings]. 
Gesundheitswesen 2010;72:692–9.
 4 Geiss K, Meyer M. Regional comparison of cancer incidence, 
mortality, and survival on the level of federal states in Germany using 
funnel plots. Eur J Cancer Prev 2019;28:234–42.
 5 Jansen L, Castro FA, Gondos A, et al. Recent cancer survival in 
Germany: an analysis of common and less common cancers. Int J 
Cancer 2015;136:2649–58.
 6 Nennecke A, Geiss K, Hentschel S, et al. Survival of cancer patients 
in urban and rural areas of Germany--a comparison. Cancer 
Epidemiol 2014;38:259–65.
 7 Hiripi E, Gondos A, Emrich K, et al. Survival from common and 
rare cancers in Germany in the early 21st century. Ann Oncol 
2012;23:472–9.
 8 De Angelis R, Sant M, Coleman MP, et al. Cancer survival in 
Europe 1999-2007 by country and age: results of EUROCARE--5- a 
population- based study. Lancet Oncol 2014;15:23–34.
 9 Rossi S, Baili P, Capocaccia R, et al. The EUROCARE-5 study on 
cancer survival in Europe 1999-2007: database, quality checks and 
statistical analysis methods. Eur J Cancer 2015;51:2104–19.
 10 Bayerisches Landesamt für Statistik. GENESIS- Online Datenbank: 
Bevölkerungsstand. Available: https://www. statistikdaten. bayern. de/ 
genesis/ online/ data? operation= abruftabelleAbrufen& selectionname= 
12411- 007s& levelindex= 1& levelid= 1554800297044& index= 13; 
[Accessed 06 Apr 2019].
 11 Meisinger C, Peters A, Linseisen J. [From the MONICA- project via 
KORA to the NAKO- study: Practical Utility of Epidemiological Studies 
in Augsburg Region]. Gesundheitswesen 2016;78:84–90.
 12 Bayerisches Krebsregister. Datenbankabfrage: region Schwaben: 
Augsburg, Stadt; Augsburg; Aichach- Friedberg; diagnose (ICD-
10) Alle bösartigen (C00- C97), 2019. Available: https://www. 
krebsregister- bayern. de/ lgl_ abfrage_ d. php [Accessed 10 Jun 2019].
 13 Silva dosS I. Cancer epidemiology: principles and methods. Geneva: 
World Health Organization, 1999.
 14 Bayerisches Landesamt für Statistik. Fortschreibung des 
Bevölkerungsstandes, 2019. Available: https://www. statistikdaten. 
bayern. de/ genesis/ online/ data? operation= abruftabelleAbrufen& 
selectionname= 12411- 007s& levelindex= 1& levelid= 1556097832727& 
index= 21, [Accessed 24 Apr 2019].
 15 Gesundheitsberichterstattung des Bundes. Im 
Informationssystem Der GBE Zur Altersstandardisierung benutzte 
Standardbevölkerungen. Gliederungsmerkmale: alter, Geschlecht, 
Standardbevölkerung, 2019. Available: http://www. gbe- bund. de/ 
oowa921- install/ servlet/ oowa/ aw92/ dboowasys921. xwdevkit/ 
xwd_ init? gbe. isgbetol/ xs_ start_ neu/& p_ aid= 3& p_ aid= 19650715& 
nummer= 1000& p_ sprache= D& p_ indsp=-& p_ aid= 19130962 
[Accessed 28 May 2019].
 16 National Cancer Institute. Joinpoint regression program. Version 
4.7.0.0, 2019. https:// surveillance. cancer. gov/ joinpoint
 17 Nennecke A, Barnes B, Brenner H, et al. [Data quality or differences 
in oncological care? - standards of reporting for cancer survival 
analyses based on registry data]. Gesundheitswesen 2013;75:94–8.
 18 Brenner H, Hakulinen T. Patients with previous cancer should not be 
excluded in international comparative cancer survival studies. Int J 
Cancer 2007;121:2274–8.
 19 Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical 
methodology. Natl Cancer Inst Monogr 1961;6:101–21.
 20 Ederer and Heise. Instructions to IBM 650 programmers in 
processing survival computations. National Cancer Institute, 1959.
 21 Statistisches Bundesamt. Sterbetafel, 2019. Available: https:// www- 
genesis. destatis. de/ genesis/ online/ data; sid= 20A1 9B2E 8DB3 2176 
8571 842E E457DB94. GO_ 2_ 2? operation= abruftabelleAbrufen& 
selectionname= 12621- 0001& levelindex= 0& levelid= 1559045500487& 
index=1
 22 Robert Koch- Institut, Zentrum für Krebsregisterdaten und 
Gesellschaft. Der epidemiologischen Krebsregister in Deutschland 
e.V. (Hrsg.). Krebs in Deutschland für 2015/16. 12. Ausgabe. Berlin, 
2019.
 23 Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key 
explanation of differences in breast cancer survival across Europe. 
Int J Cancer 2003;106:416–22.
 24 Becker N, Altenburg H- P, Stegmaier C, et al. Report on trends of 
incidence (1970–2002) of and mortality (1952–2002) from cancer in 
Germany. J Cancer Res Clin Oncol 2006;133:23–35.
 25 Simbrich A, Wellmann I, Heidrich J, et al. Trends in advanced breast 
cancer incidence rates after implementation of a mammography 
screening program in a German population. Cancer Epidemiol 
2016;44:44–51.
 26 Hermon C, Beral V. Breast cancer mortality rates are levelling off or 
beginning to decline in many Western countries: analysis of time 
trends, age- cohort and age- period models of breast cancer mortality 
in 20 countries. Br J Cancer 1996;73:955–60.
 27 Clarke CA, Purdie DM, Glaser SL. Population attributable risk 
of breast cancer in white women associated with immediately 
modifiable risk factors. BMC Cancer 2006;6:170.
 28 Brenner H, Schrotz- King P, Holleczek B, et al. Declining bowel 
cancer incidence and mortality in Germany. Dtsch Arztebl Int 
2016;113:101–6.
 29 Thiele I, Linseisen J, Heier M, et al. Time trends in stroke incidence 
and in prevalence of risk factors in southern Germany, 1989 to 
2008/09. Sci Rep 2018;8:11981.
 30 Takla A, Wiese- Posselt M, Harder T, et al. Background paper for 
the recommendation of HPV vaccination for boys in Germany. 
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 
2018;61:1170–86.
 31 Robert Koch- Institut. Aktuelles aus der KV- Impfsurveillance - 
Impfquoten ausgewählter Schutzimpfungen in Deutshland, 2018. 
Available: https://www. rki. de/ DE/ Content/ Infekt/ EpidBull/ Archiv/ 
2018/ Ausgaben/ 01_ 18. pdf?__ blob= publicationFile; [Accessed 13 
May 2020].
 32 Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends 
in cancer survival 2000-14 (CONCORD-3): analysis of individual 
records for 37 513 025 patients diagnosed with one of 18 cancers 
from 322 population- based registries in 71 countries. Lancet 
2018;391:1023–75.
 33 Eberle A, Jansen L, Castro F, et al. Lung cancer survival in Germany: 
a population- based analysis of 132,612 lung cancer patients. Lung 
Cancer 2015;90:528–33.
 34 Twardella D, Geiss K, Radespiel- Tröger M, et al. [Trends in 
incidence of lung cancer according to histological subtype 
among men and women in Germany : Analysis of cancer registry 
data with the application of multiple imputation techniques]. 
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 
2018;61:20–31.
 35 Zeiher J, Finger JD, Kuntz B, et al. [Trends in smoking among adults 
in Germany : Evidence from seven population- based health surveys 
from 1991-2015]. Bundesgesundheitsblatt Gesundheitsforschung 
Gesundheitsschutz 2018;61:1365–76.
 36 Mons U, Brenner H. Demographic ageing and the evolution of 
smoking- attributable mortality: the example of Germany. Tob Control 
2017;26:455–7.
 37 Wienecke A, Kraywinkel K. Epidemiology of head and neck cancer in 
Germany. Onkologe 2019;25:190–200.
 38 Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 
2014;383:1490–502.
 39 Ahmed S, Johnson K, Ahmed O, et al. Advances in the management 
of colorectal cancer: from biology to treatment. Int J Colorectal Dis 
2014;29:1031–42.
 40 Brenner H, Bouvier AM, Foschi R, et al. Progress in colorectal cancer 
survival in Europe from the late 1980s to the early 21st century: the 
EUROCARE study. Int J Cancer 2012;131:1649–58.
 41 Liang PS, Chen T- Y, Giovannucci E. Cigarette smoking and colorectal 
cancer incidence and mortality: systematic review and meta- 
analysis. Int J Cancer 2009;124:2406–15.
 42 Hermann S, Kraywinkel K. Epidemiology of prostate cancer in 
Germany. Onkologe 2019;25:294–303.
 43 Karim- Kos HE, de Vries E, Soerjomataram I, et al. Recent trends 
of cancer in Europe: a combined approach of incidence, survival 
and mortality for 17 cancer sites since the 1990s. Eur J Cancer 
2008;44:1345–89.
 44 Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and 
mortality patterns in Europe: estimates for 40 countries and 25 major 
cancers in 2018. Eur J Cancer 2018;103:356–87.
 on N
ovem












pen: first published as 10.1136/bm
jopen-2019-036176 on 30 A
ugust 2020. D
ow
nloaded from
 
